Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R5OU
|
||||
| Former ID |
DNC011250
|
||||
| Drug Name |
3-(benzyloxy)-9H-pyrido[3,4-b]indole
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H14N2O
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)COC2=NC=C3C(=C2)C4=CC=CC=C4N3
|
||||
| InChI |
1S/C18H14N2O/c1-2-6-13(7-3-1)12-21-18-10-15-14-8-4-5-9-16(14)20-17(15)11-19-18/h1-11,20H,12H2
|
||||
| InChIKey |
ZROLETFFKMIVMZ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Gamma-aminobutyric acid receptor subunit alpha-1 | Target Info | Inhibitor | [1] | |
| Gamma-aminobutyric-acid receptor alpha-3 subunit | Target Info | Inhibitor | [1] | ||
| Gamma-aminobutyric-acid receptor alpha-2 subunit | Target Info | Inhibitor | [1] | ||
| Gamma-aminobutyric-acid receptor alpha-5 subunit | Target Info | Inhibitor | [1] | ||
| Gamma-aminobutyric acid receptor | Target Info | Inhibitor | [1] | ||
| Gamma-aminobutyric acid receptor subunit gamma-2 | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | |||||
| GABAergic synapse | |||||
| Morphine addiction | |||||
| Nicotine addictionhsa04080:Neuroactive ligand-receptor interaction | |||||
| Nicotine addiction | |||||
| Reactome | Ligand-gated ion channel transport | ||||
| GABA A receptor activationR-HSA-975298:Ligand-gated ion channel transport | |||||
| GABA A receptor activation | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Iron uptake and transportWP2754:Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Iron uptake and transport | |||||
| References | |||||
| REF 1 | Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. Epub 2010 Sep 29.Design, synthesis, and subtype selectivity of 3,6-disubstituted |A-carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents for treatment of alcohol abuse. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.